BillionToOne, Inc.

NASDAQ:BLLN

Medical - Diagnostics & Research

Healthcare
$91.54 +0.84%

+$0.84 today

Market cap
$4.37B
Beta
0.90
P/E (TTM)
182.6
EPS (TTM)
$0.55
52W Low $61.96High $138.70

Volume 1.44M

Average 0.59M

BLLN EBITDA Margin

EBITDA as a percentage of revenue.

BillionToOne, Inc.NASDAQ: BLLN

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 10.0%

EBITDA Margin was 10.0% in Q2 FY2026, up 5.8 pp from a year earlier. On a trailing-twelve-month basis it was 12.6%, up 21.8 pp year over year.

Context

  • EBITDA Margin widened in 2 of the last 2 fiscal years.
  • FY2025 was the highest level in the 3 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 8.8% for the fiscal year ending Dec 2026, up from 6.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
10.0%-9.9 pp QoQ
Last fiscal yearDec 2025
6.5%+24.5 pp YoY
LTMJun 2026
12.6%+21.8 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+5.8 pp+1.4 pp-4.4 pp
1 year+24.5 pp+2.3 pp-22.2 pp
3 years—+3.4 pp—
5 years+4.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
6.5%
Year-over-year change
+24.5pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How BLLN compares with its peers on the latest reported figures

  • BLLN's LTM Jun 2026 EBITDA Margin of 12.6% is the 2nd highest of the 9 companies compared; the peer median is -17.5%.
  • Its year-over-year change of +21.8 pp is the 2nd highest of 9, against a peer median of +4.4 pp.
BLLN Competitors Peer median
EBITDA Margin for BLLN and competitors
Company Period LTM level YoY 3-year change
VCYTVeracyte, Inc.LTM Jun 202623.1% +13.6 pp+20.8 pp
BLLNBillionToOne, Inc.LTM Jun 202612.6% +21.8 pp—
NEONeoGenomics, Inc.LTM Jun 20261.7% +5.8 pp+10.8 pp
NTRANatera, Inc.LTM Jun 2026-6.6% +4.2 pp+53.9 pp
WGSGeneDx Holdings Corp.LTM Jun 2026-16.8% -24.5 pp+171.2 pp
FLGTFulgent Genetics, Inc.LTM Mar 2026-18.3% -9.7 pp-49.4 pp
GHGuardant Health, Inc.LTM Sep 2026-34.5% +4.7 pp+98.7 pp
MYGNMyriad Genetics, Inc.LTM Mar 2026-40.3% -32.6 pp-27.6 pp
GRALGRAIL, Inc.LTM Jun 2026-226.4% +86.1 pp+801.0 pp
Peer median (excluding BLLN) -17.5%+4.4 pp+37.4 pp

Competitors are the stored peer set for BLLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue71.73M152.58M305.11M
Cost of Revenue54.42M71.67M96.65M
Gross Profit17.31M80.92M208.46M
Gross Margin24.1%53.0%68.3%
Research & Development22.41M36.6M49.38M
Selling, General & Admin64.39M91.47M143.05M
Operating Expenses86.8M128.06M192.44M
Depreciation & Amortization6.46M11.69M11.91M
EBITDA(72.94M)(27.47M)19.76M
EBITDA Margin-101.7%-18.0%6.5%
Operating Income(69.5M)(47.15M)16.02M
Operating Margin-96.9%-30.9%5.3%
Interest Income3.46M5.82M7.75M
Interest Expense3.27M2.39M95K
Other Income / Expenses(13.18M)5.61M(8.26M)
Income Before Tax(82.67M)(41.54M)7.76M
Pre-Tax Margin-115.3%-27.2%2.5%
Income Tax Expense9K29K305K
Net Income(82.68M)(41.57M)7.45M
Net Margin-115.3%-27.2%2.4%
EPS (Basic)(1.85)(0.93)0.06
EPS (Diluted)(1.85)(0.93)0.06
Weighted Avg Shares44.72M44.72M45.8M
Weighted Avg Shares (Diluted)44.72M44.72M45.8M

BillionToOne, Inc.

NASDAQ:BLLN

Intrinsic Alpha fair value

Locked

Current Price

$91.54

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.